Co­di­ak Bio­sciences out­lines a new fo­cus for its ex­o­some plat­form in $86M IPO fil­ing

Ven­ture rais­es from mar­quee in­vestors? Check. Col­lab­o­ra­tion deal? Check. Clin­i­cal tri­al time­line? Check. For its next step, Co­di­ak Bio­sciences is head­ed for an IPO.

The S-1 re­veals lit­tle that we didn’t al­ready know about the Cam­bridge, MA-based biotech, which has a plat­form to re­pur­pose ex­o­somes as drug de­liv­ery ve­hi­cles to car­ry a range of ther­a­peu­tic pay­loads, from small mol­e­cules to pro­teins to nu­cle­ic acids. CEO Doug Williams has raised $168.2 mil­lion so far in his first gig since leav­ing the top re­search job at Bio­gen, and re­cent­ly brought in a fur­ther $56 mil­lion in up­front pay­ment from an al­liance with Jazz.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.